Physician profile
Emma Ems
NPI 1548614647
$3,586.93
in general payments reported to CMS, 2019-2025
24 companies · $752 in 2025
The $752 reported for 2025 was more than what 80% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $404 · 2022: $1,139 · 2023: $768 · 2024: $524 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $403.37 | 2023-2025 | Nuedexta, Rexulti |
| Novo Nordisk INC | $383.28 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $360.92 | 2022-2025 | Ongentys |
| Amgen INC. | $284.56 | 2021-2025 | Evenity |
| Acadia Pharmaceuticals INC | $231.53 | 2024 | Nuplazid |
| Apellis Pharmaceuticals, INC. | $207.59 | 2022-2025 | Empaveli |
| Astrazeneca Pharmaceuticals Lp | $206.87 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $129.12 | 2021-2022 | |
| Cvrx, INC. | $126.50 | 2022 | |
| Corcept Therapeutics | $125.56 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $120.83 | 2024 | Austedo Xr |
| Sumitomo Pharma America, INC. | $115.74 | 2023 | Gemtesa |
| Scynexis, INC. | $113.88 | 2022 | |
| Esperion Therapeutics, INC. | $111.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.20 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $101.20 | 2023 | Valtoco |
| Solventum Corporation | $100.00 | 2025 | V.A.C. Veraflo, V.A.C.Ulta |
| Alkermes, INC. | $100.00 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $75.59 | 2022 | |
| Ceribell, INC. | $75.25 | 2025 | Pocket Eeg Device |
| Alexion Pharmaceuticals, INC. | $69.85 | 2024 | |
| Cipher Pharmaceuticals US LLC | $17.35 | 2025 | Spinosad, Natroba |
| Lilly USA, LLC | $11.98 | 2022 | |
| Astellas Pharma US INC | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Ems listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.